Evidence map›Paper›PMID 36711006›Full record

ArticleBlood cell therapy2020

Day 0 bone marrow pathology of allogeneic hematopoietic stem cell transplantation is a novel prognostic factor in myeloid malignancies.

Takahiko Sato, Naomi Kawashima, Masafumi Ito, Yoshiko Atsuta, Yusuke Kagaya, Aika Seto, Takanobu Morishita, Nobuaki Fukushima, Yukiyasu Ozawa, Koichi Miyamura

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cell therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Takahiko SatoDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Naomi KawashimaDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Masafumi ItoDepartment of Pathology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
Yusuke KagayaDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Aika SetoDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Takanobu MorishitaDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Nobuaki FukushimaDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Yukiyasu OzawaDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Koichi MiyamuraDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
The Japanese Data Center for Hematopoietic Cell Transplantation · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Residual disease (RD) is one of the risk factors for relapse after hematopoietic stem cell transplantation (HSCT) in hematological malignancies. Although recent advances in the technology for detecting minimal/measurable RD, such as multiparameter flow cytometry and quantitative PCR, enable risk stratifications of disease relapse, these examinations still have limitations in routine clinical practice. In this study, we assessed RD in bone marrow (BM) specimens on day 0 of allogeneic HSCT by immunostaining of case-specific leukemic blast markers and analyzed the relationship between day 0 BM status and HSCT outcomes. We analyzed 82 adult HSCT recipients with myeloid malignancies. BM histology of day 0 revealed almost empty marrow with a small number of residual BM cells. However, residual blasts could be detected by immunostaining even for only a few cells. When patients were divided into two groups according to the existence of RD on day 0, those with positive RD showed significantly lower overall survival rate (27% vs. 73%,

Indexed as

allogeneic hematopoietic stem cell transplantationbone marrow pathologyminimal residual diseasemyeloid malignanciesrelapse

Identifiers

PMID36711006
PMCPMC9847277
OpenAlexW4233382049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.